Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › chronic cough

Chronic cough

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for chronic cough

19 trials tracked for chronic cough: 7 in phase 3 or 4 and 5 with published results. The most-cited published study has 308 citations.

19Trials tracked
7Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 1 Phase 3 6 Phase 2 11 Other / NA 1
  1. Phase 3 A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030) Completed · 308 cited
  2. Phase 3 A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027) Completed · 306 cited
  3. Phase 3 Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043) Completed · 37 cited
  4. Phase 3 A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038) Completed · 14 cited
  5. Phase 3 Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042) Completed · 9 cited
  6. Phase 4 Mepolizumab for the Treatment of Chronic Cough With Eosinophilic Airways Diseases Completed
Show 13 more trials
  1. Phase 3 A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension Completed
  2. Phase 2 Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033) Completed
  3. Phase 2 Evaluation of S-600918 in Adults With Refractory Chronic Cough Completed
  4. Phase 2 A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006) Completed
  5. Phase 2 A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012) Completed
  6. Phase 2 A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010) Completed
  7. Phase 2 Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough Completed
  8. Phase 2 An 8-Week Refractory Chronic Cough Study (MK-7264-021) Completed
  9. Phase 2 Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015) Completed
  10. Phase 2 Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014) Completed
  11. Phase 2 Refractory Chronic Cough Improvement Via NAL ER (RIVER) Completed
  12. Phase 2 A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough Completed
  13. N/A Sham CPAP vs. Straight CPAP for Chronic Cough Completed

Showing the 19 most-cited and recently-updated of 19 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Peri- and postmenopausal hormonal changes may exacerbate asthma, rhinitis, cough, allergies, hypersensitivity, anaphylaxis, and angioedema
Allergy & Immunology Sys. Review
Peri- and postmenopausal hormonal changes may exacerbate asthma, rhinitis, cough, allergies, hypersensitivity, anaphylaxis, and angioedema Menopause Changes Allergy Rules for Women
This systematic review examines the association between declining and fluctuating estrogen and progesterone levels and various allergic and …
Menopause can worsen allergies like hay fever and asthma because dropping estrogen levels make your immune system more reactive to triggers.
Frontiers Apr 14, 2026
Mepolizumab fails to improve refractory chronic cough in small eosinophilic airways disease trial
Allergy & Immunology RCT
Mepolizumab fails to improve refractory chronic cough in small eosinophilic airways disease trial Mepolizumab reduced inflammation but did not improve cough in a small study
A single-centre randomised controlled trial of 30 patients with refractory chronic cough and eosinophilic airways disease found subcutaneous…
Mepolizumab lowered inflammation markers in patients with chronic cough but failed to reduce their coughing or improve their quality of life…
Apr 9, 2026